SIRT1 and hepatocellular carcinoma: After treatment of three HCC cells with Sorafenib + miR-124-3p.1 inhibitor, p-FOXO3a expression was significantly higher in the si-SIRT1 group than that in the si-AKT2 group (Fig. 5B).